TScan Therapeutics (TCRX) Other Working Capital Changes (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Other Working Capital Changes of $16000.0 for Q1 2026, down 98.63% year-over-year from $1.2 million in Q1 2025, and up 100.62% quarter-over-quarter from -$2.6 million in Q4 2025.
TScan Therapeutics (TCRX) Other Working Capital Changes (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Other Working Capital Changes for 7 consecutive years, with $16000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 98.63% year-over-year to $16000.0; the TTM figure through Mar 2026 stood at -$11.5 million (down 417.54% YoY), while the FY2025 annual figure was -$10.3 million, down 648.91% from the prior year.
- Other Working Capital Changes improved to $16000.0 in Q1 2026 per TCRX's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $1.2 million in Q1 2023 and bottomed at -$2.9 million in Q2 2023.
- Historically, Other Working Capital Changes has averaged $21294.1 across 5 years, with a median of $49000.0 in 2023.
- On a YoY basis, Other Working Capital Changes climbed as much as 92703.45% in 2023 and fell as far as 12396.77% in 2023.
- TScan Therapeutics' Other Working Capital Changes stood at $4.9 million in 2022, then sank by 92.05% to $392000.0 in 2023, then soared by 928.06% to $4.0 million in 2024, then plunged by 163.7% to -$2.6 million in 2025, then soared by 100.62% to $16000.0 in 2026.
- Business Quant data shows TCRX's Other Working Capital Changes at $16000.0 in Q1 2026, -$2.6 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -483,000.00 |
| Jun 30, 2026 | -483,000.00 |
| Jun 30, 2026 | -483,000.00 |
| Mar 31, 2026 | -126,000.00 |
| Mar 31, 2026 | -126,000.00 |
| Mar 31, 2026 | -126,000.00 |
| Dec 31, 2025 | 903,000.00 |
| Dec 31, 2025 | 903,000.00 |
| Dec 31, 2025 | 903,000.00 |
| Sep 30, 2025 | -867,000.00 |
| Sep 30, 2025 | -867,000.00 |
| Sep 30, 2025 | -867,000.00 |
| Jun 30, 2025 | -35,000.00 |
| Jun 30, 2025 | -35,000.00 |
| Jun 30, 2025 | -35,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Dec 31, 2024 | -394,000.00 |
| Dec 31, 2024 | -394,000.00 |